Security key
55287L101
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 304
- Total 13F value
- $16,781
- Share change
- -19
- SEC-reported price per share
- $55.20
- Number of holders
- 1
- Value change
- -$440
- Number of buys
- 1
- Number of sells
- 1
- Shares outstanding
- 47,404,981
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
1
Top holders
1
MBX full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
MBX Biosciences, Inc. SEC filings
MBX Biosciences, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 55287L101
Recent filing periods:
Ownership snapshot
Top reported holders of MBX - MBX Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Frazier Life Sciences Pub...
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 12%
13D/G row: Frazier Life Sciences Public Fund, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Frazier Life Sciences Public Fund, L.P. leads the comparable SEC ownership view at 12%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Frazier Life Sciences Public Fund, L.P.'s linked filing trail.
Comparable ownership
Top 5
Frazier Life Sciences Public Fund...
12%
FMR LLC
11%
WELLINGTON MANAGEMENT GROUP LLP
10%
New Enterprise Associates 17, L.P.
8.1%
ORBIMED ADVISORS LLC
7.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. |
13D/G
Patrick J. Heron
|
12%
|
$72,562,680
5,224,095 shares
|
+$9,264,602 | 26 Sep 2025 |
| FMR LLC |
13D/G
13F
Company
|
11%
|
$293,826,960
5,322,885 shares
|
+$131,719,966 | 30 Jun 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
Company
|
10%
|
$274,762,754
4,977,523 shares
|
+$89,842,562 | 30 Jun 2026 |
| New Enterprise Associates 17, L.P. |
13D/G
3/4/5
Edward T. Mathers · 10%+ Owner
|
8.1%
|
$63,340,795
3,619,474 shares
|
$0 | 06 Nov 2025 |
| ORBIMED ADVISORS LLC |
13D/G
3/4/5
13F
Director, 10%+ Owner · Company
|
7.7%
|
$118,413,222
3,637,887 shares
|
-$11,880,750 | 05 Feb 2026 |
| Deep Track Capital, LP |
13F
13D/G
Company
|
6.6%
from 13D/G
|
$82,313,435
2,757,569 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
304
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
155
Q2 2026 holders
1
Holder diff
-154
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend